FDA Clears Akili’s EndeavorOTC Digital Treatment For Adults With ADHD  

Digital therapeutics company Akili said the FDA cleared its EndeavorOTC digital therapeutic treatment for adults with attention-deficit/hyperactivity disorder (ADHD). EndeavorOTC is indicated to improve attention function as measured by computer-based testing in men and women with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. 

EndeavorOTC was reviewed and cleared through FDA’s 510(k) pathway. It is available in the U.S. on the;Apple App Store and the;Google Play Store. It is the only FDA-authorized digital therapeutic for ADHD available without a prescription.;

This product is Akili . . .